Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022 https://www.cdc.gov/mmwr/volumes/71/wr/mm7107e3.htm Summary What is already known about this topic? COVID-19 vaccination during pregnancy is recommended to prevent severe illness and death in pregnant women. Infants are at risk for COVID-19–associated complications, including respiratory failure and other life-threatening complications. What is added by this report? Effectiveness of maternal completion of a 2-dose primary mRNA COVID-19 vaccination series during pregnancy against COVID-19 hospitalization among infants aged <6 months was 61% (95% CI = 31% to 78%). Effectiveness of completion of the primary COVID-19 vaccine series early and later in pregnancy was 32% (95% CI = –43% to 68%) and 80% (95% CI = 55% to 91%), respectively. What are the implications for public health practice? Completion of a 2-dose mRNA COVID-19 vaccination series during pregnancy might help prevent COVID-19 hospitalization among infants aged <6 months. (Complete study at above url)
Gates admits, “sadly” omicron is providing healthy humans with natural immunity. this is what we been saying for long time here, natural immunity beats clot shots
Omicron doesn't care if you're vaccinated or not vaccinated. Yet, it's much easier to infect someone with Covid instead of trying to get the same person to get vaccinated. In fact, a minority of the population put up a fight (protesting, threats, violence) when vaccines are mandated...Omicron doesn't have those types of obstacles. Yet, Bill Gates did not say that getting infected with Omicron will provide better protection than vaccines in preventing severe Covid infection. First, we need to have a new Variant of Concern to be birth and then infect the remainder of the population that's not vaccinated for a proper comparison of immunity from Omicron to the immunity from Vaccines. Yet, we do have the comparisons for immunity from Delta or prior Variants of Concern for comparison to the immunity from Vaccines... Vaccines do a better job in preventing severe Covid illness. Lastly, Bill Gates states that we should have done a better job in discovering/distributing mRNA vaccines as if he's comparing the timeline of that to the timeline it took for Omicron to infect the same number of populations. That's true...Omicron spread a lot faster to the global population at such speed...governments could not get their citizens vaccinated fast enough to stay ahead of Omicron. Fortunately, we had a bulk of the population (many countries > 50%) fully vaccinated prior to the arrival of Omicron. It prevented a ton of severe Covid illnesses that would have resulted in hospitalization or death. wrbtrader
Exactly! As noted by many doctors -- deliberately attempting to get Covid to get "natural immunity" while not being vaccinated is a very bad idea. Any immunity obtained is only short-term and only likely applies to that particular variant at this point (with the original Omicron). Plus there is the possibility of getting a severe case that puts you in the hospital or of being the 1 in 10 unvaccinated people who endure Long Covid. Sadly Omicron has infected many people across the world -- the variant is highly infectious. At this point it is likely the most infectious disease on the face of the earth -- even more infectious than measles in some estimates. Omicron is also vaccine evasive and having a previous infection with a variant such as Delta provides effectively no protection against Omicron. As Bill Gates noted - thanks to anti-vaxxers and a limited supply of vaccines for poor nations, Omicron is getting out to the world population faster than vaccines. It can only be hoped that Omicron infection provides some level of protection against the Omicron BA2 variant. Recent studies have found that Omicron BA2 is more infectious than the original Omicron and more deadly than Delta. If Omicron does not provide some level of protection against infection by Omicron BA2 then the unvaccinated across the globe are about to be in a world of hurt.
There's an immunology phrase that I can't remember but its proven that when a bulk of the population is fully vaccinated and then a bulk of the not vaccinated population get infected by the virus... Those remaining not vaccinated are still in danger even though they're surrounded by people with immunity from vaccines / immunity from prior Covid infections. That type of Natural Immunity is extremely risky. Statistically, these types of people wait to the end in an effort to outlast the Pandemic...most of them do in fact perish. Then there is the Crazy Covidiots that intentionally get infected with a Variant that mainly causes mild illness. That's playing a game of Russian Roulette because they do not know if they're part of that 1/3 of the population that doesn't know they have an underlying medical condition that can be exploited by the virus...resulting in severe illness or death while only causing mild illness for everybody else. wrbtrader
What a variant-proof vaccine will look like, according to scientists Medical experts are done playing whack-a-mole with these variants. https://www.mic.com/life/universal-covid-vaccine Ever spawning COVID variants have made the past two years exhausting, to say the least. I am so tired of worrying about how some tiny bizarre mutation to the spike protein of this itsy bitsy virus cell could affect me. Big Pharma recently tried to console us with promises of variant-specific vaccines, but they aren’t coming fast enough to keep up with the Greek alphabet of COVID terror. Thankfully, some forward-thinking scientists are working on a universal COVID vaccine. “You don’t want to play this whack-a-mole approach. This could go on forever,” David Martinez, a viral immunologist at the University of North Carolina at Chapel Hill, told the Washington Post. Martinez is working with other scientists at UNC to develop a vaccine with “chimeric spikes.” What that means is that, instead of using the spike protein of just one coronavirus to create a vaccine, they are using a cocktail of variants that have different spike protein mutations. The idea is that it will be more difficult for new strains to evade a vaccine that uses this multi-pronged approach, according to the Washington Post. In case you’re not a microbiologist, an analogy might be helpful here. Vaccines work by teaching our bodies to recognize and defend itself against invading viruses by showing them what potentially dangerous viruses look like. One of the problems we’ve encountered with coronavirus is that it changes so quickly that by the time our bodies are exposed to a new mutation, it looks very different from what the vaccine showed us, so our bodies don’t know how to fight it. A chimeric spike vaccine would show our bodies different variations of what the coronavirus could look like, which makes it more likely that our immune systems will build up a defense against it. Scientists in other places are using nanoparticle technology to similar effect. Since there’s a lot to be gained — both financially and for public good — in creating a universal vaccine, scientists are coming at the problem from all angles. Many experts think that striving for a universal vaccine could be a lot more effective than trying to take on each variant as it appears. “I worry about chasing variants, because there’s always going to be a new variant,” Drew Weissman, a vaccine pioneer and immunologist at the University of Pennsylvania Perelman School of Medicine who is working on a pan-coronavirus vaccine, told the Washington Post. Unfortunately, there’s no ETA as of yet. If researchers succeed in making a universal coronavirus vaccine, it will be the first of its kind. “To make a universal vaccine is an order of magnitude more complicated. Science has never been able to make a universal vaccine to anything, ever,” David Morens, an NIH researcher, told Vox. The good news is that researchers are expecting to be able release the results of the first pan-COVID vaccine human trials soon.
Covaxin to be evaluated as COVID-19 vaccine candidate in US as USFDA lifts clinical hold Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US. https://www.financialexpress.com/li...e-in-us-as-usfda-lifts-clinical-hold/2439043/ Bharat Biotech on Saturday said its Covaxin will be evaluated as a COVID-19 vaccine candidate in the US. In a statement, Ocugen Inc, Bharat Biotech’s partner in the US and Canada for Covaxin, noted that the American health regulator — the US Food and Drug Administration (FDA) — has lifted its clinical hold to evaluate the COVID-19 vaccine candidate BBV152, known as Covaxin outside the US. Covaxin (BBVI52), which has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is an investigational vaccine candidate product in the US. Ocugen Inc is co-developing the Covaxin vaccine candidate for COVID-19 in the US and Canada. “We are pleased to be able to move our clinical program for Covaxin forward, which we hope will bring us closer to offering an alternative COVID-19 vaccine,” Ocugen CEO and co-founder Shankar Musunuri said in a statement. He further said: “We firmly believe that managing this pandemic requires more than one approach to vaccines, so we are heartened to be able to continue developing our vaccine candidate.” With more than 200 million doses having been administered to adults outside the US, Covaxin is currently authorised under emergency use in 20 countries. Applications for emergency use authorisation are pending in more than 60 other countries. The World Health Organisation (WHO) recently added Covaxin to its list of vaccines authorised for emergency use. As many as 110 countries have agreed to mutual recognition of COVID-19 vaccination certificates with India that includes vaccination using Covaxin. In a separate statement on Twitter, Bharat Biotech noted that Covaxin is the only vaccine in India to have published clinical data for children 2-18 years of age, while trashing few media reports which questioned the efficacy of the jab. These trials were conducted based on regulatory approvals by the CDSCO and DCGI, it said. The vaccine was evaluated in 175 subjects in the 12-18 years age group, and 350 subjects in children below 12 years of age, it added. “It was one of the few vaccines to be evaluated in children with published data. Overall, Covaxin has more than 15 publications elucidating all aspects of the safety, immunogenicity, efficacy and effectiveness, in adults and children. This level of data transparency demonstrates a high degree of confidence in the product,” the company stated. Every batch of Covaxin requires more than 250 quality control tests before it can be released for supplies, it added. The vaccine has been administered in more than 300 million subjects globally, Bharat Biotech stated. “Since the start of the children’s vaccination program on January 3, 2022, 70 per cent of the children in the 15-18 years age group have received the first dose, and more than 25 per cent of the children in the 15-18 years age group have also received their second doses,” it said. Over 7 crore doses have been administered to children since January 2022, it added.
U.S. FDA considers approving a second COVID-19 booster shot -WSJ https://www.reuters.com/world/us/us...-second-covid-19-booster-shot-wsj-2022-02-19/ U.S. health regulators are looking at authorizing a potential fourth dose of a COVID-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter. The Food and Drug Administration has been reviewing data to authorize a second booster dose of the messenger RNA vaccines from Pfizer Inc (PFE.N) and partner BioNTech SE (22UAy.DE) and vaccines from Moderna Inc (MRNA.O), the report added. The FDA did not immediately respond to a request for comment. The agency last month cut the interval to get a booster dose of COVID-19 vaccines from Pfizer and BioNTech as well as from Moderna, in a bid to provide better protection sooner against the Omicron variant.read more The planning is still in early stages, and authorization would depend on determinations as to whether the second booster should be authorized for all adults or particular age groups, and whether it should target the Omicron variant or be formulated differently, the report said. It added that no decision was final and that it could be necessary to make booster shots available earlier if a new variant appears. The United States reported 2,323 COVID-19 deaths on Friday, bringing the total count to 936,523.